Navigation Links
Milnacipran in Medical News

Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran

NEW YORK and SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ), and Cypress Bioscience, Inc. (Nasdaq: CYPB ) will host a webcast to discuss milnacipran clinical data being presented at the American College of Rheumatology annual conference. The webcast, which...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)

...he symptoms of fibromyalgia. Savella will be marketed by Forest and its licensor, Cypress Bioscience. Pierre Fabre, who originally developed and sells milnacipran outside the U.S., licensed the rights for North America to Cypress Bioscience. Important Safety Information Savella is a selective seroto...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)

...eople in the United States. Savella will be marketed by Forest and its licensor, Cypress Bioscience. Pierre Fabre, who originally developed and sells milnacipran outside the U.S., licensed the rights for North America to Cypress Bioscience. Important Safety Information Savella is a selective seroto...

Zoloft, Lexapro the Best of Newer Antidepressants

...d in the trials were bupropion (Wellbutrin/Zyban), citalopram (Celexa), duloxetine (Cymbalta), escitalopram, fluoxetine (Prozac), fluvoxamine (Luvox), milnacipran (Savella), mirtazapine (Remeron), paroxetine (Paxil), reboxetine (Edronax/Vestra), sertraline, and venlafaxine (Effexor). Based on their analysis, ...

Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia

... analysis." "This approval is crucial for Pierre Fabre Laboratories as milnacipran is one of the flagship products of our portfolio and represents another pro...ensor, Cypress Bioscience. Pierre Fabre, who originally developed and sells milnacipran outside the U.S., licensed the rights for North America to Cypress Bioscien...

Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment

...nt of chronic constipation and constipation predominant irritable bowel syndrome; RGH-188 for the treatment of schizophrenia and bipolar disorder; and milnacipran for the treatment of fibromyalgia. In addition, the Company will support a significant Phase IV post-marketing program in support of Bystolic. These d...

Scientific poster abstracts from the 24th annual meeting of the American Academy of Pain Medicine

...notide to Predict Its Pump Infusion Effect 163 milnacipran Efficacy in the Treatment of Fibromyalgia Syndrome... Report 172 One-Year Durability of Response to milnacipran Treatment for Fibromyalgia 173 Cognitive Compl...f Visceral Pain 179 The Efficacy and Safety of milnacipran in the Treatment of Fibromyalgia 180 Lacosamid...
Milnacipran in Medical Technology

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia

NEW YORK and SAN DIEGO, Dec. 8, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) today announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for th...

Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome

NEW YORK, May 22, 2007 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and Cypress Bioscience, Inc. today announced that preliminary top-line results from a 1,196 patient randomized, three month, double-blind, placebo-controlled pivotal Phase III study demonstrate statistically significant the...

Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show

...ORK, Nov. 8 /PRNewswire/ -- Total daily dosages of milnacipran 100 mg and 200 mg demonstrated statistically signi... meeting in Boston, MA. The therapeutic effects of milnacipran among responders in a six-month study were sustain...nsion study showed that the therapeutic effects of milnacipran were sustained for up to one year of therapy. "Be...
Milnacipran in Biological Technology

Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome

NEW YORK and SAN DIEGO, Dec. 31 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) announced that they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for milnacipran, a unique dual...

US Neuropathic Pain Market Value Doubles to $5 Billion by 2018

...t 5 years due to penetration of the market for fibromyalgia. Two yet to be launched products, Forest Laboratories/Cypress Biosciences's antidepressant milnacipran and Schwarz Pharma's sodium ion channel antagonist/CRMP2 modulator lacosamide (Vimpat), will compete for market share as well as provide the benefit o...
Other Tags
(Date:7/9/2014)... , , , , ... , , , , ... 50m downrange from the firer and approximately 30cm from the bullet... , , ... , , , , , ... , , , , , , University of Southampton researchers, ...
(Date:7/9/2014)... School of Medicine of the University of Southern ... specific component of the immune system are completely ... infection. The discovery suggests that blocking this immune ... autoimmune and hyper-inflammatory diseases such as rheumatoid arthritis ... published online on June 23 in The ...
(Date:7/8/2014)... Department of Defense,s Defense Advanced Research Projects Agency ... to $2.5 million to develop an implantable neural ... neurons within the brain to help restore memory, ... builds on the understanding that memory is a ... the brain encode information, store it and retrieve ...
(Date:7/8/2014)... 2014 In a study published yesterday in the ... La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify ... currently affects over 200 million people world wide. , ... be divided into small sections or ,neighborhoods., Scientists can ... primed for gene production, by looking for a marker on ...
(Date:7/8/2014)... new NPR/Robert Wood Johnson Foundation/Harvard School of Public Health ... stress in Americans, lives finds that about half of ... stressful event or experience in the past year. Nearly ... to health. , More than half of those who ... month say too many overall responsibilities and financial problems ...
Breaking Medicine News(10 mins):Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3Health News:LJI develops new approach to identify genes poised to respond in asthma patients 2Health News:Poll finds health most common major stressful event in Americans' lives last year 2Health News:Poll finds health most common major stressful event in Americans' lives last year 3Health News:Poll finds health most common major stressful event in Americans' lives last year 4
(Date:7/9/2014)... Bacterial infections usually announce themselves with pain and fever but ... are those that are sneaky and hard to beat. Now, ... the form of tiny DNA pyramids. Published in the journal ... the nanopyramids can flag bacteria and kill more of them ... note that some infectious pathogens can lie in wait, undetectable ...
(Date:7/9/2014)... by researchers at the NIH,s National Center ... collaborators to treat sickle cell disease has ... The drug candidate, Aes-103, is the first ... mechanism of sickle cell disease. Baxter now ... for regulatory approval and commercialization. , Sickle ...
(Date:7/9/2014)... vitamin D in their blood are more likely to survive ... highest levels of vitamin D have half the risk of ... reveal. , The study is the first to correlate total ... their diagnosis which includes that produced after exposure to ... long term survival prospects. , The University of Edinburgh ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
Other Contents